4//SEC Filing
Anthera Pharmaceuticals Inc 4
Accession 0001214659-17-003496
CIK 0001316175operating
Filed
May 18, 8:00 PM ET
Accepted
May 19, 8:00 PM ET
Size
8.5 KB
Accession
0001214659-17-003496
Insider Transaction Report
Form 4
TRUEX PAUL F
DirectorPresident and CEO
Transactions
- Other
Stock option (right to buy)
2017-05-19−1,369→ 0 totalExercise: $96.64Exp: 2019-02-18→ Common Stock (1,369 underlying) - Other
Stock option (right to buy)
2017-05-19−84,376→ 0 totalExercise: $39.04Exp: 2023-05-17→ Common Stock (84,376 underlying)
Footnotes (2)
- [F1]On May 19, 2017, the reporting person and the Company agreed to cancel an outstanding stock option to purchase 1,369 shares of common stock dated February 18, 2009 (the "option"), which option was previously reported on a Form 4 filed with the SEC on February 23, 2010. 50% of the options were to vest monthly over four years beginning August 12, 2008 (the Vesting Start Date) and 50% of the options vested upon successful completion of milestones determined by the Board. The options were fully vested on August 12, 2012. The Option would expire on Feburary 18, 2019.
- [F2]On May 19, 2017, the reporting person and the Company agreed to cancel a stock option to purchase 84,376 shares of common stock dated May 17, 2013 (the "option"), which option was previously reported on a Form 4 filed with the SEC on May 21, 2013. This option was to vest annually over four years beginning March 25, 2013 (the Vesting Start Date). The Option would have completely vested on the fourth anniversary of the Vesting Start Date and would expire on May 17, 2023.
Documents
Issuer
Anthera Pharmaceuticals Inc
CIK 0001316175
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001316175
Filing Metadata
- Form type
- 4
- Filed
- May 18, 8:00 PM ET
- Accepted
- May 19, 8:00 PM ET
- Size
- 8.5 KB